- Home
- MESO vs BUSE Comparison
MESO vs BUSE Comparison
Compare MESO & BUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- BUSE
- Stock Information
- Founded
- MESO 2004
- BUSE 1868
- Country
- MESO Australia
- BUSE United States
- Employees
- MESO N/A
- BUSE N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- BUSE Major Banks
- Sector
- MESO Health Care
- BUSE Finance
- Exchange
- MESO Nasdaq
- BUSE Nasdaq
- Market Cap
- MESO 1.8B
- BUSE 2.1B
- IPO Year
- MESO N/A
- BUSE N/A
- Fundamental
- Price
- MESO $16.02
- BUSE $24.03
- Analyst Decision
- MESO Strong Buy
- BUSE Buy
- Analyst Count
- MESO 2
- BUSE 7
- Target Price
- MESO $24.00
- BUSE $26.57
- AVG Volume (30 Days)
- MESO 159.9K
- BUSE 369.9K
- Earning Date
- MESO 08-28-2025
- BUSE 10-28-2025
- Dividend Yield
- MESO N/A
- BUSE 4.16%
- EPS Growth
- MESO N/A
- BUSE N/A
- EPS
- MESO N/A
- BUSE 1.27
- Revenue
- MESO $17,198,000.00
- BUSE $583,913,000.00
- Revenue This Year
- MESO $440.77
- BUSE $62.62
- Revenue Next Year
- MESO $110.74
- BUSE $11.33
- P/E Ratio
- MESO N/A
- BUSE $18.99
- Revenue Growth
- MESO 191.39
- BUSE 30.63
- 52 Week Low
- MESO $9.61
- BUSE $18.40
- 52 Week High
- MESO $22.00
- BUSE $28.30
- Technical
- Relative Strength Index (RSI)
- MESO 52.88
- BUSE 62.18
- Support Level
- MESO $14.32
- BUSE $22.12
- Resistance Level
- MESO $15.61
- BUSE $23.49
- Average True Range (ATR)
- MESO 0.57
- BUSE 0.56
- MACD
- MESO 0.11
- BUSE 0.12
- Stochastic Oscillator
- MESO 87.78
- BUSE 96.92
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech and Wealth Management. The banking segment generates a vast majority of its revenue.